{
    "clinical_study": {
        "@rank": "158133", 
        "acronym": "ENHANCE CRT", 
        "arm_group": [
            {
                "arm_group_label": "QLV based implant strategy", 
                "arm_group_type": "Experimental", 
                "description": "QLV is the pacing site with the largest amount of dyssynchrony as measured by the LV electrical delay. The QLV based implant strategy is choosing the vein branch and the cathode with the longest QLV measurement and programming a vector based on that cathode."
            }, 
            {
                "arm_group_label": "Standard of care implant strategy", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placement of LV lead will be carried out according to the physician's standard of care implant approach"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to analyze the effect of left ventricular (LV) lead pacing\n      location  in the non-left bundle branch block (NLBBB)heart failure (HF) patient population.\n      The LV lead pacing location will be guided by either the pacing site with the largest amount\n      of dyssynchrony as measured by the LV electrical delay (QLV) or the physician's standard of\n      care implant approach."
        }, 
        "brief_title": "CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients", 
        "condition": [
            "Non-left Bundle Branch Block", 
            "Ischemic or Non-ischemic Cardiomyopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bundle-Branch Block", 
                "Heart Block", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have NLBBB morphology (includes complete right bundle branch block and\n             intraventricular conduction delay with a QRS duration > 120ms)\n\n          -  Have the following indication per the 2013 updated American College of Cardiology\n             Foundation/American Heart Association/Heart Rhythm Society (ACCF/AHA/HRS) guidelines:\n\n               -  Left ventricular ejection fraction (LVEF) \u2264 35%, sinus rhythm, ischemic or\n                  non-ischemic cardiomyopathy, a non-LBBB pattern with QRS duration \u2265 120 ms, and\n                  New York Heart Association (NYHA) class III/ambulatory class IV on guideline\n                  directed medical therapy (GDMT)\n\n          -  Receiving a new cardiac resynchronization therapy (CRT) implant or undergoing an\n             upgrade from an existing implantable cardioverter defibrillator (ICD) or pacemaker\n             implant with no more than 10% right ventricular (RV) pacing\n\n          -  Are 18 years or older, or of legal age to give informed consent specific to state and\n             local law\n\n          -  Ability to provide informed consent for study participation and is willing and able\n             to comply with the prescribed follow-up tests and schedule of evaluations\n\n        Exclusion Criteria:\n\n          -  Irreversible occlusion of venous access that will prevent placement of the CRT-ICD\n             system either through the right or left upper extremity venous system\n\n          -  Undergoing left ventricular lead placement via a surgical or epicardial approach\n\n          -  Cardiomyopathy due solely to valvular disease that is not repaired/replaced\n\n          -  Enrolled or intend to participate in a clinical drug and/or device study, which could\n             confound the results of this trial as determined by St. Jude Medical, during the\n             course of this clinical study\n\n          -  Left bundle branch block (LBBB): QRS width \u2265 120 ms, with predominantly negative QRS\n             in lead V1, and upright, monophasic QRS in leads I and V6\n\n          -  Incomplete right bundle branch block (RBBB)\n\n          -  IVCD with a QRS duration between 110 and 119ms\n\n          -  Persistent or Permanent atrial fibrillation\n\n          -  Pacemaker dependent\n\n          -  Patients who are being upgraded primarily due to RV pacing\n\n          -  Women who are pregnant or who plan to become pregnant during the clinical trial\n\n          -  Life expectancy < 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983293", 
            "org_study_id": "60037834"
        }, 
        "intervention": [
            {
                "arm_group_label": "QLV based implant strategy", 
                "intervention_name": "QLV based implant strategy", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard of care implant strategy", 
                "intervention_name": "Standard of care implant strategy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-left bundle branch block", 
            "QLV", 
            "LV lead pacing location", 
            "CRT-D"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lynchburg", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "24501"
                    }, 
                    "name": "Lynchburg General Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). A Prospective, Randomized, Postmarket, Pilot Study.", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Jagmeet Singh, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the Clinical composite score at 12 months in NLBBB patients using a standard of care versus latest electrical delay (QLV) based implant strategy. The Clinical composite score includes 4 components: New York Heart Association (NYHA)class, Patient Global Assessment (PGA), HF events, and cardiovascular death.", 
            "measure": "Improved Clinical Composite Score", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983293"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}